Home › Coronary Artery Disease › NCT07225842

The Bridging Antiplatelet Therapy With Cangrelor 2 Study

The Bridging Antiplatelet Therapy With Cangrelor 2 (BRIDGE 2) Study: A Pilot Prospective Cohort, Pharmacodynamic Study of Tailored Cangrelor Bridging Dosing Regimens

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Any patient receiving bridging with standard-dose cangrelor infusion rate of 0.75 mcg/Kg/min for at least two hours as part of their standard of care.
2. Age ≥18 years
3. Provide written informed consent.

Exclusion Criteria:

1. Need for urgent surgery
2. Confirmed or suspected pregnancy (in woman of child-bearing potential) or lactating females
3. Exposure to any oral P2Y12 inhibitor, oral anticoagulant or glycoprotein IIb/IIIa inhibitor within 48 hours.
4. Known allergy, and hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose

About the study

The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.

What is being tested

• Cangrelor (drug)

Sponsor: University of Florida · Participants: 50 · Started: Feb 18, 2026

Contact the study team

• Luis Ortega-Paz, MD, PhD · Phone: 904-244 2060
• Andrea Burton, MPH, CCRP · Phone: 904-244-5617

Official record on ClinicalTrials.gov — NCT07225842

Locations in the U.S.

Conditions

• Coronary Artery Disease

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.